Boehringer Ingelheim investigational lung cancer treatment
2012-06-11 45
Boehringer Ingelheim's investigational lung cancer treatment afatinib* prolongs progression free survival (PFS) for advanced non-small cell lung cancer patients with specific EGFR genetic mutations.
